$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Tamper resistant pharmaceutical formulations 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/24
  • A61K-047/36
  • A61K-009/20
  • A61K-031/485
  • A61K-031/165
  • A61K-031/167
  • A61K-047/02
  • A61K-047/32
  • A61K-031/5375
  • A61K-031/74
  • A61K-031/715
  • A61K-031/78
  • A61K-031/717
출원번호 US-0670651 (2015-03-27)
등록번호 US-9545448 (2017-01-17)
발명자 / 주소
  • Guido, Debora
  • Huang, Haiyong Hugh
출원인 / 주소
  • Purdue Pharma L.P.
대리인 / 주소
    Lowenstein Sandler LLP
인용정보 피인용 횟수 : 0  인용 특허 : 176

초록

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

대표청구항

1. A method for treating pain comprising administering to a patient in need thereof, a solid oral dosage form wherein the solid oral dosage form comprises: a heat-labile gelling agent;a thermal stabilizer; andan opioid agonist, wherein the solid oral dosage form releases at least about 85% of the op

이 특허에 인용된 특허 (176)

  1. Khanna Ish K. (Vernon Hills IL) Weier Richard M. (Lake Bluff IL) Collins Paul W. (Deerfield IL) Yu Yi (Skokie IL) Xu Xiangdong (Evanston IL) Partis Richard A. (Evanston IL) Koszyk Francis J. (Prospec, 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation.
  2. Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
  3. Guay Daniel (Ile Perrot CAX) Li Chun-Sing (Dollard des Ormeaux CAX), 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2.
  4. Anderson, Carter R.; Morris, Russell L., Abuse potential reduction in abusable substance dosage form.
  5. Bastin Richard James,GBX ; Lithgow Bruce Hamilton,GBX, Abuse resistant tablets.
  6. Hirsh,Jane; Kibanov,Alexander M.; Swager,Timothy M.; Buchwald,Stephen L.; Lo,Whe Yong; Fleming,Alison B.; Rariy,Roman V., Abuse-deterrent pharmaceutical compositions of opiods and other drugs.
  7. Arkenau-Maric, Elisabeth; Bartholomaus, Johannes; Kugelmann, Heinrich, Abuse-proof dosage form.
  8. Arkenau-Maric, Elisabeth; Bartholomäus, Johannes; Kugelmann, Heinrich, Abuse-proofed dosage form.
  9. Bartholomaus, Johannes; Kugelmann, Heinrich; Arkenau-Marić, Elisabeth, Abuse-proofed dosage form.
  10. Bartholomäus, Johannes; Kugelmann, Heinrich; Arkenau-Marić, Elisabeth, Abuse-proofed dosage form.
  11. Bartholomäus, Johannes; Kugelmann, Heinrich, Abuse-proofed dosage system.
  12. Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
  13. Burch, Ronald M.; Sackler, Richard S.; Goldenheim, Paul D., Analgesic combination of oxycodone and meloxicam.
  14. Burch, Ronald M.; Sackler, Richard S; Goldenheim, Paul D, Analgesic combination of oxycodone and nimesulide.
  15. Caruso Frank S., Analgesic drug composition containing a capsaicinoid and potentiator therefor.
  16. Guimberteau, Florence; Dargelas, Frédéric, Anti-misuse microparticulate oral pharmaceutical form.
  17. Saunders Richard J. (San Jose CA) Mefferd Wayne Sherman (Los Altos Hills CA), Apparatus for tracking moving workpiece by a laser beam.
  18. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) McGinity James (Austin TX) Bodmeier Roland (Austin TX), Aqueous dispersions of zein and preparation thereof.
  19. Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
  20. Keith Alec D. (Boalsburg PA) Snipes Wallace C. (Pine Grove Mills PA), Buccal drug dosage form.
  21. Reid Derek J. (London GB3) Walpole Christopher S. J. (London GB3) Wrigglesworth Roger (Kemsing GB3), Capsaicin derivatives.
  22. Chenevier, Phillippe; Marechal, Dominique, Coated particles with prolonged release and tablets containing same.
  23. Hamann Scott R., Combined antagonist compositions.
  24. Joaquina Faour AR, Combined diffusion/osmotic pumping drug delivery system.
  25. Kuczynski Anthony L. ; Childers Jerry D. ; Barclay Glen E. ; Rodriguez Susan ; Merrill Sonya, Composition and dosage form comprising opioid antagonist.
  26. Porter Garry L. (Wichita KS), Composition and method of immobilizing emetics and method of treating human beings with emetics.
  27. Porter Garry L. (507 N. Volutsia Wichita KS 67214), Composition and method to prevent accidental and intentional overdosage with psychoactive drugs.
  28. Blumberg Peter M. (Frederick MD), Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitizat.
  29. Drust Eugene G. (Norwich NY) Kasting Gerald B. (Wyoming OH) Smith Ronald L. (West Chester OH) Szkutak Joan B. (West Chester OH), Compositions for the transdermal delivery of pharmaceutical actives.
  30. Akireddy, Srinivasa Rao; Bhatti, Balwinder Singh; Cuthbertson, Timothy J.; Miller, Craig Harrison; Mitchener, Jr., Joseph Pike, Compounds.
  31. Oshlack Benjamin (New York NY), Controlled release bases for pharmaceuticals.
  32. Oshlack Benjamin (New York NY), Controlled release bases for pharmaceuticals.
  33. Oshlack Benjamin (New York NY) McGinity James (Austin TX) Chasin Mark (Manalapan NJ) Bodmeier Roland (Austin TX), Controlled release coatings derived from aqueous dispersions of zein.
  34. Leslie Stewart T. (Aberdeen GB6), Controlled release compositions.
  35. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GB2 ; Prater Derek Allan,GB2 ; Knott Trevor John,GB2 ; Mohammad Hassan,GB2, Controlled release diamorphine formulation.
  36. Goldie Robert S. (Cambridge GB2) Malkowska Sandra T. A. (Cambridge GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release dihydrocodeine composition.
  37. Frisbee, Steven, Controlled release dosage forms.
  38. DeCrosta Mark T. (Plainsboro NJ) Jain Nemichand B. (Monmouth Junction NJ) Rudnic Edward M. (Kendall Park NJ), Controlled release formulation.
  39. Jain Nemichand B. (Monmouth Junction NJ) Gertie Linda P. (Cinnaminson NJ) Rudnic Edward M. (Plainsboro NJ), Controlled release formulation.
  40. Chen Chih-Ming (Davie FL) Lee Der-Yang (Plantation FL) Xie Jianbo (Davie FL) Rodriguez Aurelio (Hialeah FL), Controlled release formulation having a preformed passageway.
  41. Ludwig Nelson H. (Greenfield IN) Ose Earl E. (Greenfield IN), Controlled release formulations and method of treatment.
  42. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  43. Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  44. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  45. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  46. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  47. Oshlack, Benjamin; Masselink, John K.; Huang, Hua-Pin; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  48. Goldie Robert S. (Comberton GB2) Malkowska Sandra T. A. (Landbeach GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
  49. Goldie Robert S. (Comberton GBX) Malkowska Sandra T. A. (Landbeach GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
  50. Krishnamurthy Thinnayam N. (Ontario CAX), Controlled release matrix suppository for pharmaceuticals.
  51. Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
  52. Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
  53. Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John Joseph (Mount Vernon NY) Kaiko Robert Francis (Weston CT), Controlled release oxycodone compositions.
  54. Oshlack Benjamin (New York NY) Minogue John J. (Mount Vernon NY) Chasin Mark (Manalpan NJ), Controlled release oxycodone compositions.
  55. Dandiker Yogendra (Ware GB3) Huckle Paul D. (Ware GB3), Controlled release pharmaceutical compositions.
  56. Tijsma,Edze Jan; Terlingen,Johannes Gijsbertus Antonius; Haas Schrijen,Saskia; Vriesema,Hein Herman, Controlled release products and processes for the preparation thereof.
  57. Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled-release formulations coated with aqueous dispersions of ethylcellulose.
  58. Swanson, Jon; Jain, Rajeev A.; Hontz, Robert; Devane, John G.; Cumming, Kenneth Iain; Clancy, Maurice Joseph Anthony; Codd, Janet Elizabeth; Liversidge, Gary, Controlled-release nanoparticulate compositions.
  59. Friend David R. ; Wong David, Delivery of drugs to the lower GI tract.
  60. Blum Melvin ; Roitberg Michael, Denatonium capsaicinate and methods of producing the same.
  61. Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
  62. Bjork, Anders K. K.; Olsson, Knut G.; Abramo, Aina L.; Christensson, Erik G., Diphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods.
  63. Shukla Atul J. (Memphis TN) Vattanasiri Anumontri (Bangkok PA THX) Nambiar Jyothi S. (Pittsburgh PA), Directly compressible granules having improved flow properties.
  64. Royce Alan E. (Effort PA), Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms.
  65. Bernardin Didier (60 Rue de Varenne 75007 Paris FRX), Display tray for aligned articles.
  66. Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke, Drug delivery system for averting pharmacokinetic drug interaction and method thereof.
  67. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  68. Hoffmeister ; Friedrich ; Hiltmann ; Rudolf ; Wollweber ; Hartmund ; Kr amer ; Helmut, Enteral pharmaceutical compositions.
  69. Oshlack Benjamin (New York NY) Leslie Stewart T. (Aberdeen GB6), Extended action controlled release compositions.
  70. Edgren David E. ; Li Shu ; Bhatti Gurdish Kaur ; Wong Patrick S. L. ; Skluzacek Robert R., Extended release dosage form.
  71. Kumar, Vijai; Dixon, David; Tewari, Divya; Wadgaonkar, Dilip B., Extended release opioid abuse deterrent compositions and methods of making same.
  72. Oshlack Benjamin ; Chasin Mark ; Huang Hua-Pin, Extruded multi-particulates.
  73. Oshlack Benjamin ; Chasin Mark ; Huang Hua-Pin, Extruded orally administrable opioid formulations.
  74. Han, Chien-Hsuan; Hou, Sui Yuen Eddie; Reid, Monica L., Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
  75. Weber Eckard (Laguna Beach CA) Keana John F. W. (Eugene OR), Glycine receptor antagonists and the use thereof.
  76. Bola Tarlok S. (Ilford GB2), Granular pharmaceutical formulations.
  77. James W. McGinity ; Feng Zhang, Hot-melt extrudable pharmaceutical formulation.
  78. Merrill Sonya ; Ayer Atul D. ; Chadha Navjot ; Kuczynski Anthony L., Hydromorphone therapy.
  79. LaHann Thomas R. (Cleves OH) Buckwalter Brian L. (Yardley PA), Hydroxyphenylacetamides having analgesic and anti-irritant activity.
  80. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ), Immediate release tablet cores of insoluble drugs having sustained-release coating.
  81. Oshlack Benjamin ; Chasin Mark, Immediate release tablet cores of insoluble drugs having sustained-release coating.
  82. Mayer, David J.; Price, Donald D.; Mao, Jianren; Lyle, John W., Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance.
  83. Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Inhibiting the development of tolerance to and/or dependence on an addictive substance.
  84. Carroll, F. Ivy; Thomas, James B.; Mascarella, S. Wayne, Kappa opioid receptor ligands.
  85. Byas-Smith Michael G., Method and compositions for controlling oral and pharyngeal pain using capsaicinoids.
  86. Horhota Stephen T. ; Saim Said, Method for extraction and reaction using supercritical fluids.
  87. Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Method for the treatment of pain.
  88. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Prater Derek Allan,GB2 ; Knott Treavor John,GB2 ; Heafield Joanne,GB2 ; Challis Deborah,GB2, Method of preparing sustained release pharmaceutical compositions.
  89. Palermo Philip J. ; Colucci Robert D. ; Kaiko Robert F., Method of preventing abuse of opioid dosage forms.
  90. Palermo, Philip J.; Kaiko, Robert F.; Colucci, Robert D., Method of preventing abuse of opioid dosage forms.
  91. Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other o.
  92. Sackler Richard ; Kaiko Robert ; Goldenheim Paul, Method of treating humans with opioid formulations having extended controlled release.
  93. Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
  94. Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
  95. Kreek Mary J. (New York NY), Method of treating patients suffering from chronic pain or chronic cough.
  96. Kreek Mary J. (New York NY) Fishman Jack (New York NY), Method of treating patients suffering from chronic pain or chronic cough.
  97. Kumar,Vijai; Dixon,David; Tewari,Divya; Wadgaonkar,Dilip B., Methods and compositions for deterring abuse of opioid containing dosage forms.
  98. Busetti Cesare,ITX ; Crimella Tiziano,ITX, Methods for treating early morning pathologies.
  99. Busetti,Cesare; Crimella,Tiziano, Methods for treating early morning pathologies.
  100. Barrett R. Cooper, Methods for treating opiate intolerance.
  101. Granger Colin D. (Chester NJ) Simon Thomas H. (Morris Plains NJ), Misuse-resistive transdermal opioid dosage form.
  102. Bhatt, Padmanabh P.; Kidane, Argaw; Edwards, Kevin, Modified release preparations containing oxcarbazepine and derivatives thereof.
  103. Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Andersen, Christine, Morphine polymer release system.
  104. Merrill Sonya (San Jose CA) Ayer Atul D. (Palo Alto CA) Hwang Paul (Campbell CA) Kuczynski Anthony L. (Mt. View CA), Morphine therapy.
  105. Merrill Sonya (San Jose CA) Ayer Atul Devdatt (Palo Alto CA) Hwang Paul (Campbell CA) Kuczynski Anthony L. (Mt. View CA), Morphine therapy.
  106. Colombo Paolo (Milan ITX) Cardona Antonio C. (Milan ITX) Pifferi Giorgio (Milan ITX), Multilayer matrix systems for the controlled release of active principles.
  107. Lau Cheuk Kun (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques-Yves (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducha, N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors.
  108. Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Belley Michel (Pierrefonds CAX), N-benzyl-3-indoleacetic acids as antiinflammatory drugs.
  109. Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
  110. Houn Simon Hsia ; David Fan, Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates.
  111. Chen Chih-Ming ; Chou Joseph C. H., Once daily pharmaceutical tablet having a unitary core.
  112. Chih-Ming Chen ; Joseph C. H. Chou, Once daily pharmaceutical tablet having a unitary core.
  113. Leys Cassius W. (Hartsdale NY) Walsh ; III Edward (Valley Cottage NY), One coat protective system for a surface.
  114. Robert F. Kaiko ; Robert D. Colucci, Opioid agonist/opioid antagonist/acetaminophen combinations.
  115. Chasin Mark ; Oshlack Benjamin ; Pedi ; Jr. Frank, Opioid formulations having extended controlled released.
  116. Gusler, Gloria; Berner, Bret; Chau, Mei; Padua, Aimee, Optimal polymer mixtures for gastric retentive tablets.
  117. Muggetti,Lorena; Martini,Alessandro; Civaroli,Paola; James,Christopher, Oral formulations for anti-tumor compounds.
  118. Shaw Irving F. (East Rockaway NY) Berk Jerome (New Rochelle NY), Orally administered drug composition for therapy in the treatment of narcotic drug addiction.
  119. Oshlack Benjamin ; Chasin Mark, Orally administrable opioid formulations having extended duration of effect.
  120. Oshlack, Benjamin; Chasin, Mark, Orally administrable opioid formulations having extended duration of effect.
  121. Wong Patrick S. L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device for administering certain drugs.
  122. Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
  123. Joaquina Faour AR; Marcelo A. Coppari AR, Osmotic device within an osmotic device.
  124. Ayer Atul D. (Mountain View CA) Theeuwes Felix (Los Altos CA), Osmotic system with distribution zone for dispensing beneficial agent.
  125. Guillaumet Grald (Orleans FRX) Flouzat Christine (Clermont Ferrand FRX) Devissaguet Michelle (Neuilly sur Seine FRX) Renard Pierre (Versailles FRX) Caignard Daniel H. (Paris FRX) Adam Grard (le Mesni, Oxazolopyridine compounds, compositions and use.
  126. Fukunaga Atsuo F. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274) Funuknaga Alex S. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274), Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine.
  127. Kelm Gary Robert ; Manring Gary Lee, Pharmaceutical dosage form for colonic delivery.
  128. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  129. Oshlack, Benjamin; Wright, Curtis; Breder, Christopher, Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent.
  130. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Knott Treavor John,GB2 ; Challis Deborah,GB2 ; Prater Derek Allan,GB2 ; Heafield Joanne,GB2, Pharmaceutical multiparticulates.
  131. Hidaka Osafumi (Akigawa JPX) Murakami Satoshi (Tachikawa JPX), Pharmaceutical plasters.
  132. Brand Larry M. (West Chester OH), Pharmaceutical products providing enhanced analgesia.
  133. LaHann Thomas R. (Cleves OH), Pharmaceutical products providing enhanced analgesia.
  134. Ducharme Yves (Montreal CAX) Gauthier Jacques Y. (Laval CAX) Prasit Petpiboon (Kirkland CAX) Leblanc Yves (Kirkland CAX) Wang Zhaoyin (Pierrefond CAX) Leger Serge (Dollard des Omeaux CAX) Therien Mic, Phenyl heterocycles as COX-2 inhibitors.
  135. Ducharme Yves (Montreal CAX) Gauthier Jacques Y. (Laval CAX) Prasit Petpiboon (Kirkland CAX) Leblanc Yves (Kirkland CAX) Wang Zhaoyin (Pierrefond CAX) Leger Serge (Dollard Des Ormeaux CAX) Therien Mi, Phenyl heterocycles as cox-2 inhibitors.
  136. Ducharme Yves (Montreal CAX) Gauthier Jacques Y. (Laval CAX) Prasit Petpiboon (Kirkland CAX) Leblanc Yves (Kirkland CAX) Wang Zhaoyin (Pierrefond CAX) Leger Serge (Dollard Des Ormeaux CAX) Therien Mi, Phenyl heterocycles as cox-2 inhibitors.
  137. Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY), Powder-layered morphine sulfate formulations.
  138. Klimesch Roger (Alsbach-Haehnlein DEX) Bleckmann Gerhard (Lampertheim DEX) Schlemmer Lothar (Maxdorf DEX), Preparation of pharmaceutical mixtures.
  139. Richard Ting ; Charles Hsiao, Press coated, pulsatile drug delivery system suitable for oral administration.
  140. Ting, Richard; Hsiao, Charles, Press coated, pulsatile drug delivery system suitable for oral administration.
  141. Gordon Maxwell (Syracuse NY) Pachter Irwin J. (Fayetteville NY), Prevention of analgesic abuse.
  142. Theeuwes ; Felix ; Saunders ; Richard J. ; Mefford ; Wayne S., Process for forming outlet passageways in pills using a laser.
  143. Ayer Atul D. (Mountain View CA) Theeuwes Felix (Los Altos CA), Process for manufacturing device with dispersion zone.
  144. Arkenau, Elisabeth; Bartholomāus, Johannes, Process for the production of an abuse-proofed solid dosage form.
  145. Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
  146. Allen, Jennifer R.; Bourbeau, Matthew P.; Chen, Ning; Hu, Essa; Kunz, Roxanne, Pyrazine compounds as phosphodiesterase 10 inhibitors.
  147. Wolfgang A. Ritschel ; Mukul A. Agrawal, Self-destructing, controlled release peroral drug delivery system.
  148. Leslie Stewart T. (Aberdeen GB6), Slow release pharmaceutical compositions.
  149. Leslie Stewart Thomas (Aberdeen SC), Slow release pharmaceutical compositions.
  150. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
  151. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
  152. Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
  153. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Prater Derek Allan,GBX ; Knott Trevor John,GBX ; Heafield Joanne,GBX ; Challis Deborah,GBX, Substained release compositions and a method of preparing pharmaceutical compositions.
  154. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Prater Derek Allan,GBX ; Knott Trevor John,GBX ; Heafield Joanne,GBX ; Challis Deborah,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
  155. Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
  156. Zhang Guohua (Parsippany NJ) Pinnamaraju Prasad (Edison NJ), Sustained release formulation containing three different types of polymers.
  157. Davis, Robert D.; Blume, Ralph W.; Keyser, Donald Jeffrey, Sustained release formulations of guaifenesin and additional drug ingredients.
  158. Morella Angelo M. (Campbelltown AUX) Fisher Mark C. (Birkenhead AUX), Sustained release pharmaceutical composition.
  159. Morella Angelo M. (Campbelltown AUX) Fisher Mark C. (Birkenhead AUX), Sustained release pharmaceutical composition.
  160. Morella Angelo M. (Campbelltown AUX) Fisher Mark C. (Birkenhead AUX), Sustained release pharmaceutical composition.
  161. Hayashida Tomohiro (Chikujo-gun JPX) Kikumaru Kadoya (Chikujo-gun JPX) Tomoyuki Omura (Takatsuki JPX), Sustained release tablet.
  162. Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
  163. Staniforth John N.,GB2 ; Sherwood Bob E. ; Hunter Edward A., Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility.
  164. James S. Chu ; Yisong Yang ; Joseph A. Fix, Tablets and methods for modified release of hydrophilic and other active agents.
  165. Conte Ubaldo (Busto Arsizio ITX) La Manna Aldo (Pavia ITX) Colombo Paolo (Pavia ITX), Tablets with controlled-rate release of active substances.
  166. Guido, Debora; Huang, Haiyong Hugh, Tamper resistant pharmaceutical formulations.
  167. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  168. Ayer Atul D. (Mt. View CA) Theeuwes Felix (Los Altos CA), Therapeutic device for osmotically dosing at controlled rate.
  169. Galiatsatos Vassilios (Stow OH) Alabakovska Lubica (Cary NC), Time-release delivery matrix composition and corresponding controlled-release compositions.
  170. Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
  171. Sharma Kuldeepak (Mountain View CA) Roy Samir D. (Mountain View CA) Roos Eric J. (Redwood City CA), Transdermal administration of buprenorphine.
  172. Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
  173. Hille Thomas (Neuwied DEX) Deurer Lothar (Koblenz DEX) Hoffmann Hans-Rainer (Neuwied DEX), Transdermal therapeutic system comprising as active component buprenorphine.
  174. Gawin Frank H. (New Haven CT) Humblestone Brian G. (Nassau BSX) Allen David F. (Nassau BSX), Treating habit disorders.
  175. Gawin Frank H. (New Haven CT) Humblestone Brian G. (Nassau BSX) Allen David F. (Nassau BSX), Treating habit disorders.
  176. Dewey, Stephen L.; Brodie, Jonathan D.; Ashby, Jr., Charles R., Treatment of addiction and addiction-related behavior.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로